Week 235 Review - A stunning start collapses to a whimper

By the end of Tuesday everything was looking pretty great. OPTI:Optibiotix continued to fly and was back in the black. I nearly wrote an excited blog post, but whenever I do that it drops back into the red again. Well, even without the blog post it dropped nearly all the way back to where it started, leaving the week up by £1,436 compared to the £8,000 is was up on Tuesday. The deficit between cost and value is now £21,575 and the total value is £85,645.

There was very little movement this week. The only big loser was TEK:Tekcapital which dropped 6% to go down to the placing price that was announced this week. I should have learnt my lesson with ALM:Allied Minds and avoided IP companies, as the inventions they invest in are rarely going to make a profit.

IQE:IQE has been making steady progress but is still a long way behind the companies it supplies. I think the market needs some convincing that they are capable of making a profit even when sales are good. I'm down 27% in my ISA, 50% in my trading account, and a horrible 59% in my SIPP. It's locked up £5,049 which I suspect will be trapped for some time yet. No share in my portfolio has fallen from grace quite so badly. I did however make £12,000 profit trading it during the shorting wars, so I have a lot to thank it for and can accept having a bit of that profit trapped for a few years.

Share of the Week is IKA:Ilika, which has been super volatile lately. It's a shame all the companies I own that are nearly back in the black seem to have a resistance point just below where I bought them, so I never seem to get into profit. I need another 9% for these to start earning money.

In the right direction, but it looked so much better on Tuesday evening.

Time to reverse that trend. I'd like to see a new line running from week 213 and heading upwards into profit.Just a matter of the 6 month wait for that to possibly happen.

The ISA and share accounts look like this

		Weekly Change
Cash	£13.44		+£1.45
Portfolio cost	£57,783.58		-£5.20
Portfolio sell value (bid price-commission)	£44,097.24	(-23.7%)	+£637.59
Potential profits	£0		+£0
Yr 5 Dividends	£0.63		+£0
Yr 5 Profit from sales	£-167.28		+£0
Yr 5 Average monthly cash profit	-£30.36	(-0.6%)	+£0.54
Total Dividends	£1,342.93		+£0
Total Profit from sales	£20,224.13		+£0
Average monthly cash profit	£393.74	(8.2%)	-£1.75
(Sold stocks profit + Dividends - Fees  / Months)
Performance/Injection	12.7%		+0%
Compound performance	57%		+0%

I didn't get my requested allocation of MAIS:Maistro shares in the open offer, so returned £5.20 to the account, but £3.75 ISA charge came out of that. The portfolio value went up £637, but still nothing in profit. OPTI:Optibiotix is only 6% down after a 1p rise, IKA:Ilika is only 9% down and JLP:Jubilee Metals is only 16% down and looking ready for a re-rate, so I'm hopeful there will be something in profit soon.

Still way too close to the orange line

If OPTI:Optibiotix can get to 100p this will be back in the black. It's got 3 weeks until I lose my last positive submission and we have a whole year in the red.

Here's the SIPP after week 219

			Weekly Change
Cash	£59.40		-£15.35
Portfolio cost	£46,995.31		+£0
Portfolio sell value (bid price - commission)	£40,103.78	(-14.7%)	+£789.16
Potential profits	£392.97		+£225.00
Yr 5 Dividends	£0		+£0
Yr 5 Interest	£0.02		+£0
Yr 5 Profit from sales	£0		+£0
Yr 5 Average monthly cash profit	-£17.30	(-0.4%)	-£4.92
Total Dividends	£1,899.24		+£0
Total Interest	£0.18		+£0
Total Profit from sales	£12,549.10		+£0
Average monthly cash profit	£276.25	(7.1%)	-£1.57
(Sold stocks profit + Dividends - Fees / Months)
Performance/Injection	11.1%		-0.01%
Compound performance	47%		+0%

Cash went down due to monthly fees. A bigger rise here than the ISA as CAML:Central Asia Metals went up a few percent on top of the OPTI:Optibiotix rise, so potential profits also went up as CAML is my only share in the black.

I should probably start to worry that my average monthly performance will soon slip below 7%. There's only MMX:minds + Machines and SBTX:SkinBioTherapeutics that can possibly help resolve this, as the others are either long term holdings or completely useless. However it's going to take quite a big profit in either of those to give me an average of 3% over 4 years. I'll need well over £1,000 which is 100% for MMX and 50% for SBTX. That's not going to happen any time soon.

What makes things worse it that I get my next injection of £2,000 next month, which will lower the performance percentage even more. I guess I could just focus on the performance based on injection, which is 11% so above target, but I set the target based on portfolio cost, so should really stick to that. In summary, I need to sell something soon with a big profit.

I'm about to hit the point where the value has crashed back down 3 times now. I really hope that doesn't happen again.

I'm the right side of the line so should be moderately happy.

Here's the trading account after week 185

		Weekly Change
Cash	£48.24		+£0
Portfolio cost	£2,321.29		+£0
Portfolio sell value (bid price - commission)	£1,323.67	(-43.0%)	+£5.01
Potential profits	£0		+£0
Year 4 Dividends	£13.20		+£0
Year 4 Profit	£0		+£0
Yr 4 Average monthly cash profit	£1.97	(1.0%)	-£0.07
Dividends	£47.92		+£0
Profit from sales	-£64.29		+£0
Average monthly cash profit	-£0.38	(-0.2%)	+£0.01
(Sold stocks profit + Dividends - Fees  / Months)
Performance/Injection	-0.2%		+0%
Compound performance	-1%		+0%

This account was meant to be fun, but it's not. Rises in several companies were blatted this week when TEK:Tekcapital went and did a placing. At least it went up a little bit. CAML:Central Asia Metals is only 17% down and the closest to enabling a sale. There's still no sign of TALY:Tally re-listing.

I think we can safely call that a year of inactivity in an account I thought I'd be buying and selling with weekly. The big mistake was buying shares with such a big spread that they were 15% down the second I bought them, or buying some of my favourite shares despite the fact that there was no evidence I was getting them cheap enough to have a likely quick rise.

The one glimmer of hope - we're the right side of the trend line.

Here's the fantasy magic formula account

			Weekly Change
Cash	£153.61		+£0
Portfolio cost	£29,846.39		+£0
Portfolio sell value (bid price - commission)	£31,010.02	(+3.4%)	+£460.48
Potential profits	£1,796.40		+£150.06
Year 1 Dividends	£0		+£0
Year 1 Profit	£0		+£0
Yr 1 Average monthly cash profit	£0	(0%)	+£0
Dividends	£0		+£0
Profit from sales	£0		+£0
Average monthly cash profit	£0	(0%)	+£0
(Sold stocks profit + Dividends - Fees  / Months)

Not a bad week, with value increasing by £460, £150 of which was increased paper profits.

The house builders are still doing best, up around 20%, and the dodgy AIM shares are still doing the worst, down around 14%. Friday was a pretty awful day, with only 3 of the 30 companies increasing in value.

At the moment, this method of picking shares would be doing very well for me, as long as I avoid AIM companies. It's going to be realy difficult next month though, as with CAML:Central Asia Metals still really cheap, and almost in the top 30 anyway, how am I going to resist buying those instead of holding my nerve and starting to build a magic formula portfolio for real?

Week 234 Review - Big gains for Optibiotix

A great week for OPTI:Optibiotix, climbing 8p. That would have been worth £8,400 but the portfolio only gained by £7,268 as there were some big drops elsewhere. It was still a great week, with the deficit between cost and value cut to £23,012 and total portfolio value rising to £84,227.

JLP:Jubilee Metals was the biggest loser, dropping 12% on profit taking and losing about £500 value. Now those sells are out of the way I anticipate a steady rise into profitability, unless they shoot themselves in the foot like they usually do.

IKA:Ilika kept going up and up, but is now going down and down. There was a 7% drop this week so they are 16% down now after getting within a whisker of being in the black.

SBTX:SkinBioTherapeutics is suffering as people sell them to buy OPTI:Optibiotix, or at least that's what seems to happen when one of the two companies does well. This will languish until the next deal turns up. It was meant to be "imminent" before Christmas, so hopefully there won't be too much longer to wait.

TRMR:Tremor almost recovered last week's losses and climbed 8% this week. Things are looking fairly good for this going into the black in the next 6 months so I can actually make a trade in my so-called trading account.

Share of the Week is my beloved OPTI:Optibiotix. The 8p climb is 12% and I just need the same again next week to get into profit.

Rather volatile I think.

The trend line is quite steep now, so it's going to take some turning around.

Here's the ISA and share accounts

		Weekly Change
Cash	£11.99		+£0
Portfolio cost	£57,788.78		+£19.83
Portfolio sell value (bid price-commission)	£43,459.65	(-24.8%)	+£3,770.93
Potential profits	£0		+£0
Yr 5 Dividends	£0.63		+£0
Yr 5 Profit from sales	£-167.28		+£0
Yr 5 Average monthly cash profit	-£30.90	(-0.6%)	+£1.24
Total Dividends	£1,342.93		+£0
Total Profit from sales	£20,224.13		+£0
Average monthly cash profit	£395.49	(8.2%)	-£1.70
(Sold stocks profit + Dividends - Fees  / Months)
Performance/Injection	12.7%		-0.1%
Compound performance	57%		+0%

The cost went up by £19.83 as I foolishly applied for MAIS:Maistro shares in their open offer. The shares are no longer traded on the AIM market, but I figured the risk of flushing £20 down the drain to take my holding to 200,000 shares was worth it, just in case they manage to salvage anything from the mess. I don't hold out much hope, but the most I can possibly lose is the £142 I've put in so far, which isn't going to break the bank.

Aside from that, most of the rise is down to OPTI:Optibiotix, and there's still nothing in profit after IKA:Ilika and JLP:Jubilee Metals decided to go into reverse just before they went green.

Still a long way below the red line, but thank goodness we didn't cross the orange.

Still £15K in the red and it's almost been in the red for a whole year.

Here's the SIPP after week 218

			Weekly Change
Cash	£74.75		+£0
Portfolio cost	£46,995.31		+£0
Portfolio sell value (bid price - commission)	£39,314.62	(-16.3%)	+£3,490.11
Potential profits	£167.97		-£195.00
Yr 5 Dividends	£0		+£0
Yr 5 Interest	£0.02		+£0
Yr 5 Profit from sales	£0		+£0
Yr 5 Average monthly cash profit	-£12.38	(-0.3%)	+£1.38
Total Dividends	£1,899.24		+£0
Total Interest	£0.18		+£0
Total Profit from sales	£12,549.10		+£0
Average monthly cash profit	£277.82	(7.1%)	-£1.28
(Sold stocks profit + Dividends - Fees / Months)
Performance/Injection	11.2%		+0%
Compound performance	47%		+0%

Great increase thanks to OPTI:Optibiotix, but CAML:Central Asia Metals dropped by another 3% and slashed my potential profits by £195. This is now at the level where I feel I should buy some more.

Nearer the red line than the orange - very good.

Only about £8K in the red, but for over 6 months now.

The trading account looks like this after week 184

		Weekly Change
Cash	£48.24		+£0
Portfolio cost	£2,321.29		+£0
Portfolio sell value (bid price - commission)	£1,318.66	(-43.2%)	+£7.54
Potential profits	£0		+£0
Year 4 Dividends	£13.20		+£0
Year 4 Profit	£0		+£0
Yr 4 Average monthly cash profit	£2.04	(1.1%)	-£0.08
Dividends	£47.92		+£0
Profit from sales	-£64.29		+£0
Average monthly cash profit	-£0.39	(-0.2%)	+£0
(Sold stocks profit + Dividends - Fees  / Months)
Performance/Injection	-0.2%		+0%
Compound performance	-1%		+0%

Hardly any change, as the increase in TRMR:Tremor was almost zapped by drops in everything else. Things are going on with TALY:Tally beta testing their app, so hopefully we won't have too long to wait for them to lift the suspension so I can see whether it's going to be possible to get rid of them.

Just bumbling along in a state of desperation.

The right side the the trend line, and it's a shallow one - but trapped rather a long way below the zero line.

Here's the fantasy magic formula account

			Weekly Change
Cash	£153.61		+£0
Portfolio cost	£29,846.39		+£0
Portfolio sell value (bid price - commission)	£30,549.54	(+2.4%)	-£620.08
Potential profits	£1,646.34		-£252.08
Year 1 Dividends	£0		+£0
Year 1 Profit	£0		+£0
Yr 1 Average monthly cash profit	£0	(0%)	+£0
Dividends	£0		+£0
Profit from sales	£0		+£0
Average monthly cash profit	£0	(0%)	+£0
(Sold stocks profit + Dividends - Fees  / Months)

A pretty dreadful week, dropping £620 on value, £252 of which was reduced profits. The house builders are all still doing very well, around 20% up. Lots of shares have tanked though, with KAZ:Kaz Minerals and BUR:Burford Capital both down 14%, BMN:Bushveld Minerals down 12% and DGOC:Diversified Gas & Oil down 11%. Those are all AIM shares or shares I would avoid on environmental grounds, so when I put this into practice for real I should be a bit safer.

That's it - I'm just hoping OPTI:Optibiotix has some momentum behind the share price now, as  there's visibility of cash coming in and some gigantic deals ramping up. A Sweetbiotix announcement would light the blue touch paper.

Week 233 Review - Slight recovery but some big drops too.

Although OPTI:Optibiotix climbed 3p, the portfolio climbed less than that due to some big drops elsewhere, most notably CAML:Central Asia Metals. The value improved by £2,909 and the deficit between cost and value narrowed to £30,281, with total value now at £76,939.

Biggest loser was last week's Share of the Week TRMR:Tremor, which gave up 10% of the 16% rise. I knew it was too good to be true that one of the shares in my trading account might be turning around.

IKA:Ilika was Share of the Week the 2 weeks before that, and just as it was about to go into the black, dropped 9% this week and is looking shaky again. Let's hope it was just profit taking.

TLOU:Tlou Energy gave a rather cautious statement about the progress of de-watering the gas beds which triggered a 9% drop on fears that the flows won't be strong enough for a commercial operation. The statement said all indications were still good, but there's more water than was initially anticipated. The key will be maintaining a consistent flow of gas.

I really don't know what could have justified CAML:Central Asia Metals dropping 7% this week. Copper prices are holding, and they were under-priced before the drop. It hammered my performance this week as I hold a lot of these.

Some rare good news for IQE:IQE which climbed 5% this week. Even my best account is 33% down, with my worst a shocking 62% down. We really need the new reactors producing wafers and the 5g infrastructure orders to start roling in.

OPTI:Optibiotix recovered 3p which was 5%, but are still 19% down and losing £14K. I yearn for some news on SweetBiotix which could be the turning point for the share price.

SBTX:SkinBioTherapeutics also recovered from its sympathy dip by 5% in my ISA and 7% in my SIPP. I'm really considering buying some more of these if I dispose of IKA:Ilika or MMX:Minds + Machines, neither of which I regard as long term investments.

Having said that, MMX:Minds + Machines is Share of the Week after a 6% rise has taken it within 3% of being in the black. Do I wait for a dividend announcement or flog them for a small profit so I can get more SBTX?

It looks a disappointingly tiny blip upwards on this chart.

As long as we're still above the trend line I'll be moderately happy.

The ISA and share accounts look like this

			Weekly Change
Cash	£11.99		+£0
Portfolio cost	£57,768.95		+£0
Portfolio sell value (bid price-commission)	£39,668.89	(-31.3%)	+£1,677.46
Potential profits	£0		+£0
Yr 5 Dividends	£0.63		+£0
Yr 5 Profit from sales	£-167.28		+£0
Yr 5 Average monthly cash profit	-£32.14	(-0.7%)	+£1.34
Total Dividends	£1,342.93		+£0
Total Profit from sales	£20,224.13		+£0
Average monthly cash profit	£397.19	(8.3%)	-£1.71
(Sold stocks profit + Dividends - Fees  / Months)
Performance/Injection	12.8%		+0%
Compound performance	57%		+0%

Not much to show other than the OPTI:Optibiotix gains caused most of the uplift. Still no shares in profit, but a few very close.

We didn't cross the orange line, but came very close.

Any upward momentum has vanished of the left hand side. It's 12 months of declining value and every time I think a recovery is about to happen, it plunges downwards again.

The SIPP looks like this after week 217

			Weekly Change
Cash	£74.75		+£0
Portfolio cost	£46,995.31		+£0
Portfolio sell value (bid price - commission)	£35,824.51	(-23.8%)	+£1,283.75
Potential profits	£362.97		-£420.00
Yr 5 Dividends	£0		+£0
Yr 5 Interest	£0.02		+£0
Yr 5 Profit from sales	£0		+£0
Yr 5 Average monthly cash profit	-£13.76	(-0.4%)	+£1.72
Total Dividends	£1,899.24		+£0
Total Interest	£0.18		+£0
Total Profit from sales	£12,549.10		+£0
Average monthly cash profit	£279.10	(7.1%)	-£1.30
(Sold stocks profit + Dividends - Fees / Months)
Performance/Injection	11.2%		-0.1%
Compound performance	47%		+0%

More than half my profits in CAML:Central Asia Metals were wiped out, severely limiting the size of the uplift in value and vexing me considerably.

Below halfway between the injection line and the cost line, which is bad.

Same story of continuous 12 month decline as we see in the ISA.

The trading account looks like this after week 183

		Weekly Change
Cash	£48.24		+£0
Portfolio cost	£2,321.29		+£0
Portfolio sell value (bid price - commission)	£1,311.12	(-43.5%)	-£52.18
Potential profits	£0		+£0
Year 4 Dividends	£13.20		+£0
Year 4 Profit	£0		+£0
Yr 4 Average monthly cash profit	£2.12	(1.1%)	-£0.08
Dividends	£47.92		+£0
Profit from sales	-£64.29		+£0
Average monthly cash profit	-£0.39	(-0.2%)	+£0
(Sold stocks profit + Dividends - Fees  / Months)
Performance/Injection	-0.2%		+0%
Compound performance	-1%		+0%

Most of last weeks gains have gone with big falls for CAML:Central Asia Metals and TRMR:Tremor.

The recovery didn't last.

Some comfort that we're above the trend line.

I've not reported on my magic formula account while I was on holiday, so here's how it performed over the three weeks

			Weekly Change
Cash	£153.61		+£0
Portfolio cost	£29,846.39		+£0
Portfolio sell value (bid price - commission)	£31,169.62	(+4.4%)	+£68.89
Potential profits	£1,898.42		+£366.96
Year 1 Dividends	£0		+£0
Year 1 Profit	£0		+£0
Yr 1 Average monthly cash profit	£0	(0%)	+£0
Dividends	£0		+£0
Profit from sales	£0		+£0
Average monthly cash profit	£0	(0%)	+£0
(Sold stocks profit + Dividends - Fees  / Months)

Potential profits are up by £366 but some losses deepened so overall value is only up by £68. Key thing is it's doing better than my real accounts!

The best performing share is an old holding of mine TW.:Taylor Wimpey, up by 26%, closely followed by BDEV:Barratt Developments up 21% and PSN:Persimmon at 20%. All the house builders seem to be on a Brexit roll.

The worst performers are BUR:Burford Capital down 15% and BMN:Bushveld Minerals down 11%, both of which are in the more risky AIM category and which my due diligence may well filter out of any real purchases.

That's the holiday catch-up finished. Let's hope for a nice week and some form of recovery - and dare I hope for a share to go into profit? IKA:Ilika, MMX:Minds + Machines and JLP:Jubilee Metals are all really close.

Week 232 Review - Desperate misery as Optibiotix crashes despite great trading update

Unbelievable - the OPTI:Optibiotix trading update was exactly what was expected, in fact it exceeded expectations as there was an extra £500K owed by companies where we couldn't book the money in the accounts, and that will all come through in H1 of 2020. A 7p drop in share price was the main culprit for this week's drop of £7,380, widening the gap between cost and value to £33,190 and reducing overall value to £74,030.

As mentioned above, the worst performer this week was my biggest holding
OPTI:Optibiotix, dropping 11%. The volatility of this share price is massively frustrating. I know I should relax and be patient, as rewards will be reaped in the future, but it's hard when you are sitting on such big paper losses.

SBTX:SkinBioTherapeutics dropped 10% in sympathy I think, with my SIPP holding 19% down and my ISA holding 40% down on purchase price. There should be a second big deal announced soon, and hopefully this one will promise revenues a bit sooner than the last. Again, as a patient investor it shouldn't be an issue that income is 2 years away. I should just be buying more while they are cheap.

JLP:Jubilee Metals had a good week, climbing 5% and getting to within 3% of being in profit. It's been a long wait, but hope has really been kindled for these.

RDT:Rosslyn Data climbed an impressive 8%, but they are still 67% down and I fear a long way from getting back into the black. This is a very small holding for me though.

IKA:Ilika march forward another 12% and are only down by commission now. If someone had asked me to list the order of the shares that I would expect to return to the black next, this one would have been well down the list.

Share of the week is TRMR:Tremor, which climbed a whopping 16% but is still 32% down in my trading account. I think there's a good chance these are going to recover now.

Back into deep trouble

The only ray of sunshine is we're still above the trend line.

The ISA and share portfolios look like this

			Weekly Change
Cash	£11.99		+£0
Portfolio cost	£57,768.95		+£0
Portfolio sell value (bid price-commission)	£37,991.43	(-34.2%)	-£3,885.76
Potential profits	£0		+£0
Yr 5 Dividends	£0.63		+£0
Yr 5 Profit from sales	£-167.28		+£0
Yr 5 Average monthly cash profit	-£33.48	(-0.7%)	+£1.45
Total Dividends	£1,342.93		+£0
Total Profit from sales	£20,224.13		+£0
Average monthly cash profit	£398.90	(8.3%)	-£1.73
(Sold stocks profit + Dividends - Fees  / Months)
Performance/Injection	12.8%		-0.2%
Compound performance	57%		+0%

Huge drop, nearly all of which is down to OPTI:Optibiotix.

Only just above the injection line.

Here's the SIPP after week 216

			Weekly Change
Cash	£74.75		+£0
Portfolio cost	£46,995.31		+£0
Portfolio sell value (bid price - commission)	£34,540.76	(-26.5%)	-£3,575.41
Potential profits	£782.97		+£30.00
Yr 5 Dividends	£0		+£0
Yr 5 Interest	£0.02		+£0
Yr 5 Profit from sales	£0		+£0
Yr 5 Average monthly cash profit	-£15.48	(-0.4%)	+£2.21
Total Dividends	£1,899.24		+£0
Total Interest	£0.18		+£0
Total Profit from sales	£12,549.10		+£0
Average monthly cash profit	£280.40	(7.2%)	-£1.30
(Sold stocks profit + Dividends - Fees / Months)
Performance/Injection	11.3%		+0%
Compound performance	47%		+0%

Same OPTI:Optibiotix problem as the ISA, but CAML:Central Asia Metals climbed a little to raise potential profits by £30

Still a healthy buffer here.

Here's the trading account after week 182

		Weekly Change
Cash	£48.24		+£0
Portfolio cost	£2,321.29		+£0
Portfolio sell value (bid price - commission)	£1,363.30	(-41.3%)	+£82.07
Potential profits	£0		+£0
Year 4 Dividends	£13.20		+£0
Year 4 Profit	£0		+£0
Yr 4 Average monthly cash profit	£2.20	(1.1%)	-£0.09
Dividends	£47.92		+£0
Profit from sales	-£64.29		+£0
Average monthly cash profit	-£0.39	(-0.2%)	+£0
(Sold stocks profit + Dividends - Fees  / Months)
Performance/Injection	-0.2%		+0%
Compound performance	-1%		+0%

Nice week, with lots of rises, but still no prospect of a sale.

It's been going in the right direction for a few weeks now.

I'm reasonably hopeful this lot will turn around.

That's it - no more for this catch-up week.

Week 231 Review - Not a lot happened

I'm on a post-holiday catch-up so the next 2 updates will be brief and just act as a record of where we were at the end of each week. Not a bad week, with portfolio value dropping by £952 and the deficit between cost and value widening to £25,810. Total value is £81,409.

The only big mover was IKA:Ilika, which rose 13% on the back of a 14% rise last week wo earn Share of the Week again.This is now only 12% down.

Here's the ISA and share accounts snapshot

			Weekly Change
Cash	£11.99		-£3.75
Portfolio cost	£57,768.95		+£0
Portfolio sell value (bid price-commission)	£42,329.65	(-27.5%)	-£452.46
Potential profits	£0		+£0
Yr 5 Dividends	£0.63		+£0
Yr 5 Profit from sales	£-167.28		+£0
Yr 5 Average monthly cash profit	-£34.93	(-0.7%)	+£0.85
Total Dividends	£1,342.93		+£0
Total Profit from sales	£20,224.13		+£0
Average monthly cash profit	£400.63	(8.3%)	-£1.81
(Sold stocks profit + Dividends - Fees  / Months)
Performance/Injection	13.0%		+0%
Compound performance	57%		+0%

The biggest drop was caused by a 1p fall in OPTI:Optibiotix.

Here's the SIPP after week 215

			Weekly Change
Cash	£74.75		-£16.22
Portfolio cost	£46,995.31		+£0
Portfolio sell value (bid price - commission)	£38,116.17	(-18.9%)	-£498.64
Potential profits	£752.97		+£60.00
Yr 5 Dividends	£0		+£0
Yr 5 Interest	£0.02		+£0.01
Yr 5 Profit from sales	£0		+£0
Yr 5 Average monthly cash profit	-£17.69	(-0.4%)	-£8.77
Total Dividends	£1,899.24		+£0
Total Interest	£0.18		+£0.01
Total Profit from sales	£12,549.10		+£0
Average monthly cash profit	£283.34	(7.2%)	-£1.33
(Sold stocks profit + Dividends - Fees / Months)
Performance/Injection	11.3%		-0.1%
Compound performance	47%		+0%

Similar story to above, but an extra £60 on CAML:Central Asia Metals potential profits and cash and year 5 monthly average profits down due to monthly charges.

Here's the trading portfolio after Week 181

		Weekly Change
Cash	£48.24		+£0
Portfolio cost	£2,321.29		+£0
Portfolio sell value (bid price - commission)	£1,281.23	(-44.8%)	-£1.57
Potential profits	£0		+£0
Year 4 Dividends	£13.20		+£0
Year 4 Profit	£0		+£0
Yr 4 Average monthly cash profit	£2.29	(1.2%)	-£0.09
Dividends	£47.92		+£0
Profit from sales	-£64.29		+£0
Average monthly cash profit	-£0.39	(-0.2%)	+£0
(Sold stocks profit + Dividends - Fees  / Months)
Performance/Injection	-0.2%		+0%
Compound performance	-1%		+0%

Hardly any change here

Week 230 Review - Santa buggered off

It was all looking so positive, even up to this morning, with many of my holdings up significantly. However OPTI:Optibiotix plunged today and ruined the week and what I hoped was a great start to the year. The portfolio value dropped by £5,693 and the deficit between cost and value widened to £24,858 with the overall value dropping to £82,3982.

Worst performer and only major faller was OPTI:Optibiotix which dropped 6p or 9%. That would have cost me £6,300 so it shows the other shares were up by £600. I guess the traders are taking their 10% from when they bought in the late 40's.

JLP:Jubilee Metals started to move again, climbing 6% and this is only 10% down now. The next production figures should see a re-rate.

MMX:Minds + Machines are also starting to motor, with a 9% climb this week meaning they are only 7% down altogether. I really hope they announce a dividend.

Share of the Week is IKA:Ilika which went up by 14% but is still 25% down. I think there's a feeling the car battery technology may pay off so folks are piling in. I'm still keen to pile out as I'm not convinced they have a clue about how to be commercial.

Blip or trend?

At least we're still pulling the trend line flatter.

Here's the performance of the ISA and share accounts

			Weekly Change
Cash	£15.74		+£0
Portfolio cost	£57,768.95		+£0
Portfolio sell value (bid price-commission)	£42,329.65	(-26.7%)	-£3,034.00
Potential profits	£0		+£0
Yr 5 Dividends	£0.63		+£0
Yr 5 Profit from sales	£-167.28		+£0
Yr 5 Average monthly cash profit	-£35.78	(-0.7%)	+£1.70
Total Dividends	£1,342.93		+£0
Total Profit from sales	£20,224.13		+£0
Average monthly cash profit	£402.44	(8.4%)	-£1.76
(Sold stocks profit + Dividends - Fees  / Months)
Performance/Injection	13.0%		+0%
Compound performance	57%		+0%

Pretty much all of the drop is down to OPTI:Optibiotix, just one week after I was hoping to report that it was back in profit.

Every time is starts looking promising, down we go again.

Still on the right side of the trend line, but in a few weeks there will be nothing left in the black.

The SIPP looks like this after week 214

			Weekly Change
Cash	£90.97		+£0.01
Portfolio cost	£46,995.31		+£0
Portfolio sell value (bid price - commission)	£38,614.81	(-17.8%)	-£2,694.21
Potential profits	£707.97		+£60.00
Yr 5 Dividends	£0		+£0
Yr 5 Interest	£0.01		+£0.01
Yr 5 Profit from sales	£0		+£0
Yr 5 Average monthly cash profit	-£8.92	(-0.2%)	+£1.79
Total Dividends	£1,899.24		+£0
Total Interest	£0.18		+£0.01
Total Profit from sales	£12,549.10		+£0
Average monthly cash profit	£283.34	(7.2%)	-£1.33
(Sold stocks profit + Dividends - Fees / Months)
Performance/Injection	11.4%		+0%
Compound performance	47%		+0%

Similar story to the ISA, but at least CAML:Central Asia Metals climbed by £60 potential profits, and I spotted 1p interest earned in December - yippee!

Still just above halfway between the orange and red lines

I have almost 6 months before all the above zero values disappear.

The trading account looks like this after week 180

		Weekly Change
Cash	£48.24		+£0
Portfolio cost	£2,321.29		+£0
Portfolio sell value (bid price - commission)	£1,282.80	(-44.7%)	+£34.98
Potential profits	£0		+£0
Year 4 Dividends	£13.20		+£0
Year 4 Profit	£0		+£0
Yr 4 Average monthly cash profit	£2.38	(1.2%)	-£0.11
Dividends	£47.92		+£0
Profit from sales	-£64.29		+£0
Average monthly cash profit	-£0.39	(-0.2%)	+£0.01
(Sold stocks profit + Dividends - Fees  / Months)
Performance/Injection	-0.2%		+0%
Compound performance	-1%		+0%

Another reasonable week, with small increases in most of the shares. CAML:Central Asia Metals is now only 12% down, so there is a vague hope something could happen here.

Who am I trying to kid - this is still way down on just a few months ago.

Just above the trend line though

Here's the virtual magic formula account

			Weekly Change
Cash	£153.61		+£0
Portfolio cost	£29,846.39		+£0
Portfolio sell value (bid price - commission)	£30,920.30	(+3.6%)	-£180.43
Potential profits	£1,350.65		-£180.81
Year 1 Dividends	£0		+£0
Year 1 Profit	£0		+£0
Yr 1 Average monthly cash profit	£0	(0%)	+£0
Dividends	£0		+£0
Profit from sales	£0		+£0
Average monthly cash profit	£0	(0%)	+£0
(Sold stocks profit + Dividends - Fees  / Months)

Quite impressive that the reduction in value is accounted for by a reduction in paper profits down to just a few pence. Best performer is EVR:Evraz, up 12.21% since I "bought" them, and worst performer is BMN:Bushveld Minerals, down by 12.17%.

No updates for a few weeks now as I'm off on holiday, but I'll take weekly snapshots and do a big catch-up at the end of January. By then OPTI:Optibiotix will have issued a trading statement, SBTX:SkinBioTherapeutics may have announced their second deal, JLP:Jubilee Metals may have re-rated, MMX:Minds+Machines may have hinted at a dividend, and TALY:Tally may have lifted their suspension. We can but hope.